Preclinical News and Research

RSS

Soligenix' LPM oral drug delivery technology receives Hong Kong patent

Soligenix, Inc., a late-stage biotechnology company, announced today that it has received a Hong Kong patent which addresses its Lipid Polymer Micelle (LPM™) technology for the improved oral delivery of drugs. The issued Hong Kong patent, HK 1071054, entitled "Stabilized Reverse Micelle Compositions and Uses Thereof" covers lipid structures (reverse micelles) that promote the intestinal absorption of peptides and other sensitive drugs that cannot otherwise be given orally.

17 Feb 2010

Special issue reviews current state of science in fetal therapy

Repairing birth defects in the womb. Inserting a tiny laser into the mother's uterus to seal off an abnormal blood flow and save fetal twins. Advancing the science that may allow doctors to deliver cells or DNA to treat sickle cell anemia and other genetic diseases before birth.

17 Feb 2010

Embera NeuroTherapeutics establishes clinical development partnership for its cocaine dependence program

Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for drug dependence, smoking cessation and obesity, announced today that the company has retained Exponential Pharma Ventures LLC to assist in establishing a clinical development partnership for its cocaine dependence program with a fully integrated pharmaceutical company.

17 Feb 2010

Positive topline data from Alkermes' phase 1 clinical study of ALKS 37 announced

Alkermes, Inc. today announced positive topline data from a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC).

16 Feb 2010

Oncolytics Biotech receives U.K. MHRA approval for REOLYSIN combination Phase 3 trial

Oncolytics Biotech Inc. today announced that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that the Company previously reached an agreement on with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process.

16 Feb 2010

EntreMed's ENMD-2076 for AML receives FDA's orphan drug designation

EntreMed, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AML).

16 Feb 2010

Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency

Octapharma AG today announced the start of the first of a series of Phase III studies for its new 10% high purity intravenous immunoglobulin (IVIG). The study will investigate the efficacy and safety of this novel immunoglobulin in the treatment of primary immune deficiency and, together with results from additional upcoming studies, will support its regulatory filing in Europe and the US.

16 Feb 2010

Idera Pharmaceuticals presents TLR antagonist preclinical hyperlipidemia data at Keystone Symposia conference

Idera Pharmaceuticals, Inc. presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference “Advances in Molecular Mechanisms of Atherosclerosis” being held in Banff, Alberta, Canada. Idera’s proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and present a potentially innovative approach for the treatment of certain autoimmune diseases.

15 Feb 2010

Debiopharm receives AFSSAPS approval of CTA for Debio 0932 inhibitor, triggers milestone payment to Curis

Curis, Inc., announced today that its licensee Debiopharm S.A. has received approval from France's regulatory authority Agence Française de Securité Sanitaire des Produits de Santé (AFSSAPS) of a Clinical Trial Application (CTA) for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of Curis’ and Debiopharm’s August 2009 license agreement, Curis will receive an $8 million milestone payment from Debiopharm for the achievement of this development objective.

12 Feb 2010

Better and standardized animal models needed for musculoskeletal regenerative medicine

Clinical testing and development of novel therapies based on advances in tissue engineering and regenerative medicine that will one day enable the repair and replacement of diseased or damaged human muscle, bone, tendons, and ligaments depends on the availability of good animal models.

12 Feb 2010

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.

12 Feb 2010

Amicus Therapeutics presents additional data from Amigal Phase 2 extension study for Fabry disease

Amicus Therapeutics announced today additional positive preliminary data from its ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease at the Lysosomal Disease Network WORLD Symposium in Miami, Florida.

11 Feb 2010

PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study

PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.

11 Feb 2010

Excelimmune receives $1M investment as part of open Series-B financing round

Excelimmune, Inc. announced today they have received a $1 million investment as part of an open Series-B financing round. The investment comes from a mixture of existing and new investors.

11 Feb 2010

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

3SBio Inc., a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a Phase I clinical trial for NuPIAO to the Chinese State Food and Drug Administration (SFDA).

11 Feb 2010

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.

11 Feb 2010

$NovaShunt initiates study to evaluate AFS for refractory ascites patients$

NovaShunt initiates study to evaluate AFS for refractory ascites patients

NovaShunt today announced the initiation of its pivotal multi- center clinical study named PIONEER, a Prospective, multi-center, open label, non-randomized study to Investigate the safety and perfOrmance of the Automated Fluid ShuNt in patiEnts with ascitEs and diuretic Resistance.

11 Feb 2010

PROMETA Treatment Program rapidly reduces cravings for methamphetamine subjects: Study

Hythiam, Inc. announced today that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA® Treatment Program on methamphetamine dependent subjects were published in the Journal of Psychopharmacology, a peer-reviewed, international journal that publishes original research and review articles on preclinical and clinical aspects of psychopharmacology.

11 Feb 2010

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

4SC AG a drug discovery and development company focused on autoimmune and cancer indications, today announced the first treatment in a Phase I study evaluating 4SC-205, an oral Eg5 kinesin spindle protein inhibitor, in patients with solid tumours or malignant lymphomas.

11 Feb 2010

Preclinical News and Research

Soligenix' LPM oral drug delivery technology receives Hong Kong patent

Special issue reviews current state of science in fetal therapy

Embera NeuroTherapeutics establishes clinical development partnership for its cocaine dependence program

Positive topline data from Alkermes' phase 1 clinical study of ALKS 37 announced

Oncolytics Biotech receives U.K. MHRA approval for REOLYSIN combination Phase 3 trial

EntreMed's ENMD-2076 for AML receives FDA's orphan drug designation

Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency

Idera Pharmaceuticals presents TLR antagonist preclinical hyperlipidemia data at Keystone Symposia conference

Debiopharm receives AFSSAPS approval of CTA for Debio 0932 inhibitor, triggers milestone payment to Curis

Better and standardized animal models needed for musculoskeletal regenerative medicine

Second-quarter fiscal 2010 results announced by Pharmacyclics

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

Amicus Therapeutics presents additional data from Amigal Phase 2 extension study for Fabry disease

PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study

Excelimmune receives $1M investment as part of open Series-B financing round

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

NovaShunt initiates study to evaluate AFS for refractory ascites patients

PROMETA Treatment Program rapidly reduces cravings for methamphetamine subjects: Study

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News